PCV152 TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN THE US  by Angalakuditi, M et al.
A178 Abstracts
reference measure) and one ﬁngerstick analyzed by the Hemochron POC device. 
Consistent with published FDA recommendations, the previous standard QA analysis 
included linear regression, correlation and Bland Altman analysis. The novel QA 
analysis features thorough descriptive analysis and a validated method to estimate 
when INR measures lead to the same clinical decision. RESULTS: 1,666 paired INRs 
were collected. Standard QA analysis deemed the Hemochron device acceptable. 
Notably, the correlation between the Hemochron and laboratory was 0.9. Our novel 
analysis revealed the Hemochron never reported seven INR values: 2.1, 2.7, 3.1, 3.5, 
3.8, 4.1, and 4.4. Furthermore, the Hemochron systematically inﬂated lower INRs 
and deﬂated higher values. Consequently, 30% (503 / 1,666) of clinical decisions were 
predicted to differ using the Hemochron. The laboratory was nearly twice as likely to 
report an INR below the target range (RR: 1.9, 95% CI: 1.7–2.1) than the Hemo-
chron. CONCLUSIONS: Standard QA analysis missed clinically important deﬁcien-
cies in the Hemochron device. Our novel analysis revealed the Hemochron does not 
report all INR values and leads to incorrect clinical decisions an unacceptably large 
proportion of times. The Hemochron device has been replaced in our institution. QA 
analyses should be reported in explicitly clinical terms so decision-makers understand 
the implications to patient care.
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OBJECTIVES: To examine the association between venous thromboembolism (VTE) 
events and hospital quality for patients who underwent major orthopedic surgery. 
METHODS: Based on 2005–2007 national Medicare claims, all patients who under-
went major orthopedic surgery were identiﬁed. Rates for patients who had a VTE 
event during their initial hospitalization were calculated. By using the CompQualTM 
scoring algorithm, every provider in the Medicare dataset was ranked according to 
their quality. This algorithm, with an empirical Bayesian approach, combines volume 
and mortality rate of hospitals to create an index score. Hospitals are ranked in 
quintiles. Logistic regression was used to see the effect of quality on VTE event rates. 
RESULTS: We obtained a sample that included 642 patients in the pulmonary embo-
lism (PE) only group, 1950 patients in the deep vein thrombosis (DVT) only group, 
and 153 patients in the both PE and DVT group. After controlling for patients’ 
demographic and clinical factors, VTE events in low quality hospitals were almost 2.5 
times higher than VTE events in high quality hospitals (p = 0.000). CONCLUSIONS: 
Any policy implementation that would decrease the variation in hospital quality would 
have a direct effect on the rates of VTE events.
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QUALITY OF PHARMACEUTICAL CARE PROVIDED IN A CHRONIC 
DISEASE: GEOGRAPHIC VARIATION, PROCESS OF CARE MEASURES 
AND CLINICAL OUTCOMES
Johnson ML, Agarwal S, Aparasu R, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: To determine association of recommended pharmacotherapy in CHF 
with geographic variation in clinical outcomes. METHODS: Veterans with at least 
one outpatient visit with CHF diagnosis from FY2000–2001 were included in a 
cohort. Patients with non-utilization of VA for two years were excluded. Twenty-two 
Veteran Integrated Service Network (VISNs) of the VA were geographic units of 
analyses. Outcomes evaluated were: death, all-cause hospitalization and heart failure 
hospitalization. Recommended pharmacotherapy was measured by use of ACE inhibi-
tors, ARBs and Beta-blockers. Follow up period was one year post index date of CHF 
diagnosis. We accounted for patient factors (gender, race, age, co-morbidities, severity 
of illness, co-medications, adherence) and process of care measures (prescription of 
recommended pharmacotherapy). Multivariate logistic regression models were used 
to calculate observed-to-expected (O/E) ratios across VISNs. Separate models were 
constructed accounting for patient factors, process of care measures and structure 
(VISNs). We ranked the outliers and interpreted, in context of, the quality of phar-
maceutical care provided. RESULTS: We analyzed 125,239 CHF cases with enough 
power to detect differences across VISNs. About 60% patients were on ACE inhibi-
tors, 8% on ARBs and 49% on Beta Blockers. Factor of variance in prescription rates 
ranged from 1.11 to 2.79. Strong correlation was observed between prescription rates 
and outcome rates (−0.48 to −0.54). c-indexes for all the models were above 0.7. 
Change in the outlier status, from the model containing patient factors versus the 
model with patient factors and process of care factors, indicated change in the quality 
of pharmaceutical care provided by the VISNs. CONCLUSIONS: In 1998, VA imple-
mented Quality Enhancement Research Initiative (QUERI) to systemize quality 
improvement. During FY2000–02, signiﬁcant variations were observed in prescription 
and outcome rates, despite efforts to synchronize quality of care. Differential prescrip-
tion rates and differential adherence rates led to the variations in the outcomes.
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OBJECTIVES: To assess the utilization of secondary preventive medications after an 
acute myocardial infarction (AMI) in a state Medicaid population. METHODS: The 
study was a retrospective cohort analysis using a state Medicaid claims database. The 
study cohort was identiﬁed based on inpatient claims for discharges with either a 
primary or secondary diagnosis code for AMI (ICD-9 code: 410.XX) between January 
1, 2002 and December 31, 2006. The study cohort was restricted to patients who 
were < 65 years old and were enrolled in the traditional fee-for-service program. 
Utilization of secondary preventive medications was considered appropriate if patients 
ﬁlled at least 1 prescription for each of the recommended medications (angiotensin-
converting enzyme (ACE) inhibitors /angiotensin-receptor blockers, beta-blockers, and 
statins) in the 90 days after discharge. Logistic regression analysis was used to identify 
demographic and clinical predictors associated with the recommended utilization of 
secondary preventive medications. RESULTS: The ﬁnal study cohort consisted of 752 
patients discharged following hospitalization for AMI. The mean age of the cohort 
was 53±7.9 years and there were a higher proportion of females (59%) and whites 
(84.6%) in the study sample. Only 43.25% of the patients appropriately utilized all 
the recommended medications after AMI. Regression analysis indicated that use of 
percutaneous transluminal coronary angioplasty (PTCA) procedures during the hos-
pitalization (OR = 2.64; 95% CI:1.78–3.89); having a diagnosis of hyperlipidemia 
(OR = 1.71; 95% CI:1.17–2.51), hypertension (OR = 2.00; 95% CI:1.18–3.39) or 
asthma (OR = 0.56; 95% CI:0.37–0.87); and utilization of the recommended medica-
tions prior to hospitalization (OR = 2.42;95% CI:1.30–4.50) were signiﬁcant predic-
tors of appropriate utilization of secondary preventive medications. CONCLUSIONS: 
Post-AMI patients in a state Medicaid program had sub-optimal utilization of second-
ary preventive medications; however, the utilization rates were higher than in previous 
studies that primarily focused on an older cohort of patients.
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OBJECTIVES: The study evaluated medication utilization pattern of patients aged 50 
years and older with systolic hypertension (SH) in a primary care setting. Speciﬁc 
objectives were: 1) to assess the prevalence of comorbid conditions by patient demo-
graphics, and 2) to study the utilization of antihypertensive classes based on compel-
ling indications. METHODS: Retrospective analysis was conducted using GE 
Centricity electronic medical records (EMR) from a large primary care physician 
group. Patients with SH (ICD-9-CM 401.xx) with systolic blood pressure (SBP) 
>140 mmHg, diastolic blood pressure (DBP) <90 mmHg, 50 years and older, continu-
ously enrolled in the database and having 12 months pre- and post-index date observa-
tions were identiﬁed. Patients on dialysis were excluded from the study. Demographics, 
ofﬁce visits, clinical measures, compelling indications for antihypertensive treatment 
and comorbidities, drug regimens over a 2-year period were collected. Descriptive 
analysis was performed using SPSS version 17. RESULTS: A total of 22,074 patients 
had hypertension out of which 1,616 met the inclusion/exclusion criteria for SH. Mean 
age was 68.88±11.38 years; 59.03% females, and 78.4% had one or more compelling 
indications/comorbidities. Hyperlipidemia was the most prevalent comorbid condition 
(70.9%, n = 1,145), followed by diabetes (24.7%, n = 399) and coronary artery disease 
(15.6%, n = 252). A total of 16.4% of SH patients were on statins, followed by CCBs 
(16.2%) and ACEIs (15.3%). By compelling indications (top medication class), 18.8% 
patients with diabetes were taking CCBs, 16.9% patients with hyperlipidemia were 
taking CCBs, and 15.8% patients with CAD were taking ACEIs. CONCLUSIONS: 
Evidence from large clinical trials demonstrate that appropriate use of antihypertensive 
therapy in patients with SH and compelling indications reduces the incidences of 
stroke, myocardial infarction, and heart failure. Thus, it is important for physicians 
to follow the Seventh Joint National Committee (JNC 7) guidelines to improve quality 
of care and health outcomes in patients with SH.
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OBJECTIVES: Oral therapies that target nitric oxide signaling (sildenaﬁl) or endothe-
lin signaling (bosentan and ambrisentan) are used to treat pulmonary arterial hyper-
tension (PAH). We studied the treatment patterns, resource utilization, and costs 
associated with these three oral therapies in a US population of commercially insured 
patients. METHODS: This was a retrospective study using claims from a large health 
insurance database. Commercial and Medicare Advantage patients with claims indi-
cating PAH between January 2006 and December 2008 and whose ﬁrst PAH treat-
ment was for ambrisentan, bosentan, or sildenaﬁl were selected for study inclusion. 
PAH treatment patterns, PAH-related utilization, and PAH-related costs were assessed 
during a minimum 6 month follow-up period. RESULTS: A total of 727 patients were 
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identiﬁed for study inclusion. Sildenaﬁl was the most common initial treatment (n = 
455 patients), followed by bosentan (n = 251 patients) and ambrisentan (n = 21 
patients). On average, ambrisentan patients received one pill/day with a daily dose of 
7 mg, bosentan patients received 2 pills/day with a daily dose of 222 mg, and sildenaﬁl 
patients received 2.3 pills/day with a daily dose of 61 mg. Approximately 44% of 
ambrisentan, 35% of bosentan, and 25% of sildenaﬁl patients experienced a dose 
increase (p = 0.013) during the follow-up period. PAH-related inpatient and emergency 
department utilization were similar among the groups, while ambulatory visits differed 
among the groups, with average monthly counts of 1.2, 0.8, and 0.5 visits for ambris-
entan, bosentan, and sildenaﬁl patients (p < 0.001). Follow-up total PAH-related costs 
were signiﬁcantly different among the groups, with average monthly costs of $6820, 
$5332, and $3632 for ambrisentan, bosentan, and sildenaﬁl patients (p = 0.020). Cost 
differences were primarily driven by PAH-related pharmacy costs, which were signiﬁ-
cantly lower in sildenaﬁl patients (p < 0.001). CONCLUSIONS: Of the three oral 
PAH treatments studied, sildenaﬁl was the most frequently prescribed, and was associ-
ated with lower pharmacy and overall costs than either ambrisentan or bosentan.
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FAILURE OF THE BLAND-ALTMAN METHOD TO IDENTIFY CLINICALLY 
IMPORTANT DISAGREEMENT BETWEEN MEASURES OF THE 
INTERNATIONAL NORMALIZED RATIO
Shermock KM
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OBJECTIVES: The Bland-Altman method is often upheld as the optimal method to 
assess agreement between alternate measures of the same clinical parameter. However, 
recent research by our group demonstrates the Bland-Altman method does not report 
agreement in a clinically meaningful way. The objective was to determine if the Bland-
Altman method distinguished between two point-of-care (POC) INR devices. These 
devices were previously shown to have signiﬁcantly different levels of agreement with 
our core laboratory. METHODS: In a previous experiment, 170 patients provided 
three separate INR measures at the same clinic visit—two by POC (AvosureTM and 
ProTimeTM devices) and one venous sample analyzed at our core laboratory (consid-
ered the standard measure). Agreement was achieved when the POC and lab INR 
values led to the same clinical decision. Differences in agreement between the POC 
devices and laboratory were assessed by McNemar’s test. In the current study, we 
applied the Bland-Altman method to determine if inferences regarding agreement 
between the POCs and laboratory were identical to the previous experiment where 
clinical decisions deﬁned agreement. RESULTS: The Avosure device was signiﬁcantly 
more likely to lead to the same clinical decision as the laboratory versus the ProTime 
device (80% vs. 66%, respectively, p < 0.001). However, the Bland-Altman method 
produced virtually identical mean bias (0.4 and 0.5 INR units, respectively) and did 
not distinguish between the devices. Statistical analysis of the Bland-Altman method 
produced the same ﬁndings for each device: signiﬁcantly different standard deviations 
between the POC and the laboratory (p < 0.001), signiﬁcant bias in each device (p < 
0.001), and high correlations between the POCs and the laboratory (0.925 and 0.926, 
respectively). CONCLUSIONS: The Bland-Altman method did not detect clinically 
important differences between the POC INR devices. Clinically meaningful agreement 
between measures of INR is optimally assessed by a method that directly observes or 
explicitly estimates clinical decisions.
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OBJECTIVES: To determine the proportion of the post-surgery prophylaxis period 
that warfarin-treated patients undergoing total hip or total knee replacement (THR/
TKR) spent in the American College of Chest Physicians (ACCP)-recommended thera-
peutic international normalized ratio (INR) range using two methods: within-patient 
proportion and Rosendaal linear interpolation. METHODS: Using an electronic data-
base, patients undergoing total THR/TKR between January 1, 2004 and January 31, 
2009 who received warfarin within 3 days after surgery were identiﬁed and followed 
for up to 90 days. Analysis focused on Day 5 onward¯since warfarin takes several 
days to reach therapeutic effect¯and on patients with at least 2 measured INR levels 
during this period. INR results were categorized based on ACCP guidelines: in range 
(2–3), below range (<2), or above range (>3). The proportion of INR levels within 
each range was determined for each patient, and the distribution of these within-
patient proportions computed. Time within each range was imputed using the Rosend-
aal method, which assumes a linear interpolation between observed measurements, 
applying an INR level to each treatment day. RESULTS: A total of 653 THR and 871 
TKR patients were identiﬁed; both groups had a median of 5 INR measurements from 
Day 5. Median within-patient percentages of in-range INR values were 33% for the 
average THR patient and 29% for the average TKR patient. Using the Rosendaal 
method, THR patients spent a median 29% and TKR patients a median 28% of 
within-patient proportion of time within the INR 2–3 range. CONCLUSIONS: The 
within-patient proportion of actual INR values and the proportion of imputed days 
spent in the ACCP-recommended therapeutic range (2–3) were similar in this post-
surgical cohort of THR/TKR patients. Regardless of the method, the majority of INR 
values among all patients were outside of the ACCP-recommended INR therapeutic 
range.
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OBJECTIVES: To develop a methodology to link patients from two de-identiﬁed 
databases and leverage unique data from both to measure the impact of blood pressure 
and clinical ﬁndings on total costs. METHODS: Hypertensive patients (ICD-9 diag-
nosis 401.xx-405.xx) were identiﬁed from the MarketScan Commercial and Medicare 
Supplemental administrative claims databases (MarketScan) and the GE Centricity 
Electronic Medical Record (EMR) database (Centricity) for the years 2004–2008. A 
hybrid approach of deterministic and probabilistic matches was developed to identify 
common patients. Patients were included if they matched on zip code, gender and 
month of birth, and had at least three matching ofﬁce visit dates at a rate of 75% or 
higher. Patients were followed for 12 months after the initial diagnosis. MarketScan 
provided data on enrollment, all reimbursed services (medical and drug) and costs, 
and Centricity provided clinical and biometric details, such as body mass index (BMI) 
and blood pressure. RESULTS: Among the 3 million MarketScan and 1.5 million 
Centricity patients with hypertension, 31,786 met the matching criteria. Mean age 
was 58 and 54% were female. The demographic and clinical characteristics of these 
patients did not vary substantially from those of the two data sources. Among the 
31,786 patients, 84% received drug treatment, 56% had a BMI over 30 and mean 
systolic and diastolic values were 134 and 81, respectively. Mean unadjusted costs 
were $9,338 for patients with consistently controlled (ﬁrst and last systolic <140 and 
diastolic < 90) hypertension and $8,773 for patients not consistently controlled. 
CONCLUSIONS: A combined probabilistic and deterministic approach of linking 
patients yielded a sample size large enough to conduct a study and leverage the 
strengths of administrative and EMR data. Initial ﬁndings suggest that controlled 
patients incur higher costs, however, adjustments have not been made for additional 
demographic, clinical, and treatment characteristics.
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OBJECTIVES: Log models are widely used to deal with skewed outcomes, such as 
health care costs. They improve precision of estimates and diminish the inﬂuence of 
outliers. Smearing estimation suggested in literature only works with homoskedastic 
or heteroskedastic errors due to categorical variables. Generalized linear models 
(GLM) have been proposed as an alternative to deal with any kind of heteroskedastic-
ity but recent literature shows that log models are superior to GLM under certain 
conditions. We present a method using log transformation that accounts for any kind 
of heteroskedasticity in the estimation of health care cost METHODS: Assume there 
is a population represented by the random vector of explanatory variables (ex. patient 
and clinical characteristics) and with the scalar response variable (ex. health care costs) 
and we want to estimate unknown parameters. Assume that error terms are in function 
of explanatory variables, and therefore heteroskedasticity exists. By modeling hetero-
skedasticity separately, we created a weight function and using this weight in an 
outcomes model, we corrected the heteroskedasticity in the log transformed model. 
Retransformation was done by adjusting for heteroskedasticity. RESULTS: As a case 
study, we calculated the burden of illness of venous thromboembolism (VTE). The 
difference between the cost of VTE and non-VTE patients is estimated to be $6,345 
and $8,239 depending on whether the proposed or a GLM model is used. The stan-
dard errors changed signiﬁcantly depending on the model. The difference was signiﬁ-
cant with the log transformed model with heteroskedasticity-adjusted standard errors 
and the GLM model. However, the difference was insigniﬁcant when the adjustment 
was not done. CONCLUSIONS: Log transformation provides more efﬁcient estima-
tors than GLM models under certain conditions (ex. if there is excess kurtosis) and 
heteroskedasticity can be adjusted even if its form is unknown.
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ACCOUNTING FOR TRIAL-EXCLUDED MEDICAL CONDITIONS WHEN 
SIMULATING MORTALTIY IN CLINICAL TRIAL POPULATIONS
Smolen H, Klein R, Myers J
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BACKGROUND: Clinical trials frequently exclude patients likely to die within the 
trial timeframe. Thus, these highly-selected patients have lower initial mortality prob-
abilities relative to the age- and gender-matched general population. OBJECTIVES: 
To capture the effect that clinical trial exclusion criteria have on intermediate-term 
(i.e., one- to ﬁve-year) death probabilities in study subjects with substantial asymp-
tomatic carotid artery stenosis. METHODS: We “phased-in” certain relevant death 
probabilities in a microsimulation model using data from the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The phase-in process initially eliminates or greatly 
reduces the mortality probability from a condition (reﬂecting patients excluded with 
